Table S1.

Study cohort for neuropathology studies

Case	Patient demographics			PMI, h	Staging		LB nos.
	Age, y	Sex, f/m	Clinicopathological diagnosis		Braak PD	Braak AD	SN	AC	EC
1	87	m	ILB	24	5	1	11	3*	4*
2	77	m	ILB	36	4	1	30	2*	3*
3	77	f	ILB	34	N/A	1	10	0*	0*
4	82	m	ILB	29	5	1	11	3*	1*
5	82	m	PD	48	6	1	25	26	22
6	77	m	PD	72	6	1	15	30	25
7	72	m	PD	48	4	1	11	1*	3*
8	92	m	PD	36	6	1	16	25	15
9	86	m	PD	66	6	1	18	11	11
10	76	m	PDD/DLB	72	6	1	21	10	13
11	80	f	PDD/DLB	96	6	2	34	72	213
12	72	m	PDD/DLB	48	6	2	75	121	71
13	79	m	PDD/DLB	96	6	2	85	91	197
14	76	m	PDD/DLB	52	6	2	119	249	175
15	92	m	PDD/DLB	24	5	1	24	8	22
16	76	f	PDD/DLB	96	6	1	53	28	29
17	72	m	PDD/DLB	34	6	1	34	73	258
18	80	f	PDD/DLB	72	6	2	28	N/A*	106
19	71	m	PDD/DLB	88	6	1	50	17	31
20	80	m	PDD/DLB	37	6	2	10	78	119

Characterization of the 20 cases in terms of neuropathological staging and LB numbers in three brain areas (substantia nigra, anterior cingulate cortex, and entorhinal cortex). Clinicopathological diagnoses: AD, Alzheimer’s disease; DLB, dementia with Lewy bodies; ILB, incidental Lewy body cases; PD, Parkinson’s disease; PDD, Parkinson’s with dementia; PMI, postmortem interval. Staging is according to Braak PD and Braak AD. LB burden is in mean absolute values of quantification triplets, blinded for case and diagnosis. N/A, section not available.

^*Low LB measures; these cases were excluded from statistical analysis.